Phase III study of Zevalin [ibritumomab tiuxetan Y-90] and BEAM [carmustine, etoposide, cytarabine and melphalan] compared with BEAM alone prior to autologous hematopoietic stem cell transpl. [transplantation] in pts [patients] relapse of non-Hodgkins lymphoma
Phase of Trial: Phase III
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Carmustine; Cytarabine; Etoposide; Melphalan
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 22 Feb 2011 Status changed from not yet recruiting to active, no longer recruiting.
- 05 Jul 2007 New trial record.